This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Series A generates impressive $104mm for Adaptimmune
27 Sep 2017
Adaptimmune Ltd. (developing T-cell therapies for cancer and infectious diseases) closed an oversubscribed Series A financing of $104mm. New Enterprise Associates led and was joined by other first-time backers OrbiMed Advisors, Wellington Management Co., Fidelity Biosciences, Foresite Capital Management, Ridgeback Capital Management, Novo AS, QVT, Rock Springs Capital, venBio Select, and Merlin Nexus, along with returning investors including the University of Oxford and others.
Gene Therapy, Cell Therapy
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?